UCB Inc. (United States)

UCB is a Belgian global biopharmaceutical company focused on neurology and immunology. Key products include Cimzia (certolizumab pegol) for rheumatoid arthritis, Crohn’s disease, and psoriasis, Briviact and Vimpat for epilepsy, and Neupro for Parkinson’s disease and restless legs syndrome. UCB’s patient-centric approach drives innovation in severe diseases affecting the nervous and immune systems.